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Depression is common in patients on haemodialysis and associated with adverse outcomes. 
Antidepressant use is widespread though evidence of efficacy is limited.  
Objectives 
To study antidepressant management practices in patients on haemodialysis with reference 
to NICE guidelines on management of depression in adults with chronic physical health 
problems.  
Design 
Prospective, multicentre, longitudinal cohort study with 6-15 month follow-up.  
Participants 
Patients on haemodialysis established on antidepressant medication. 
Measurements 
Baseline assessment of mood was undertaken using Beck Depression Inventory (BDI-II). 
Demographic, clinical, and medication data was also collected. Changes in clinical and life 
circumstances, and medication during follow-up were recorded. At follow-up, BDI-II was 
reassessed and diagnostic psychiatric assessment undertaken.  
Results 
Forty-one patients were studied. General Practitioners were the main prescribers (68%). Ten 
agents were in use, the commonest being Citalopram (39%). Doses were often sub-optimal. 
At baseline, 30 patients had high BDI-II scores (≥16) and 22 remained high at follow-up. Eleven 
had BDI-II <16 at baseline. In five this increased on follow-up to ≥16. Sixteen patients (39%) 
had no medication review during follow-up, 14 (34%) had a dose review, and 11 (27%) a 
medication change. On psychiatric assessment at follow-up, eight patients had current major 
depressive disorder (MDD), seven recurrent, and 20 evidence of past MDD. Six displayed no 
evidence of ever having MDD.  
Conclusions 
Antidepressant management in patients on haemodialysis reflected poor drug selection, 
over-prescription, under-dosing and inadequate follow-up suggesting sub-optimal adherence 
to NICE guidelines. Most patients had high depression scores at follow-up. Antidepressant use 









Depression is common in patients on haemodialysis (HD). Estimates of prevalence varies 
between 23 - 39% dependent on methods used (Palmer et al., 2013, Watnick et al., 2005). 
Diagnosis is challenging due to symptom overlap between depression and advanced chronic 
kidney disease (CKD), particularly fatigue and other somatic complaints (Chilcot et al., 2010). 
Depression is associated with reduced quality of life and increased mortality and may lead 
to reduced treatment adherence and self-care behaviour, and greater healthcare resource 
use (Abdel-Kader et al., 2009, Hedayati et al., 2010, Chilcot et al., 2011, Rosenthal Asher et 
al., 2012, Weisbord et al., 2014). 
Literature review on management of depression in CKD 
Management of depression in patients receiving HD is difficult. A recent systematic review, 
carried out under the auspices of the European Renal Best Practice Group, identified only 
one small and inconclusive RCT and recommended well-designed RCTs in this setting (Nagler 
et al., 2012). Since then there have been three RCTs. The ASSertID study was a feasibility 
RCT of sertraline versus placebo in patients on HD. There was no benefit of sertraline over 
placebo on depression severity over a six-month period, though there were more 
withdrawals related to adverse effects in the sertraline group (Friedli et al., 2017). A larger 
placebo-controlled study of sertraline in CKD patients not on dialysis, also found no benefit 
of sertraline over placebo on mood, though there were more adverse effects in the 
sertraline group (Hedayati et al., 2017). In a third study there was a marginal, statistically 
but not clinically significant benefit on mood of sertraline over cognitive behavioural 
therapy (CBT), though there was no control group (Mehrotra et al., 2019). On the other 
hand, benefits of group (Duarte et al., 2009)  and chair side (during centre-based HD) CBT 
have been reported (Cukor et al., 2014). Hence though there is some evidence for the 
benefits of CBT in this setting, there is no firm evidence for the use of antidepressants, and 
some evidence for an increased prevalence of adverse effects.  
Indeed CKD may increase the risk of adverse events associated with antidepressants. Some 
drugs or their active metabolites may be excreted by the kidney and therefore retained in 
patients with CKD. The condition leads to a disturbed internal milieu, which may 
substantially change the pharmacokinetic and pharmacodynamic properties of the drug 
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(Gabardi and Abramson, 2005). CKD is also associated with accelerated heart disease 
(Bansal, 2017) and many antidepressants are potentially cardiotoxic (Assimon et al., 2019). 
Polypharmacy is rife in patients with CKD especially those on dialysis. This significantly 
increases the potential for drug interactions(Mason and Bakus, 2010).  
In addition to the excess of adverse effects noted above (Friedli et al., 2017, Hedayati et al., 
2017), use of antidepressants has also been associated with increased risks of altered 
mental status, falls, and fractures in older patients receiving HD (Ishida et al., 2019). 
Furthermore there is an increased mortality risk in HD patients on those SSRIs with a higher 
propensity to increase QT interval compared to those with lesser propensity (Assimon et al., 
2019), though whether use of antidepressants is associated with an increased risk over that 
associated with depression itself, is not known.   
Notwithstanding all this – a large proportion of patients on HD are on antidepressants, in the 
US, in excess of 20% (Assimon et al., 2019, Saran et al., 2018).  In our recent ASSertID study 
(Friedli et al., 2017), we found that a significant proportion of the HD cohort (11%) at baseline 
screening was currently taking antidepressants, and that around 20% had previously used 
these agents.  There are no specific UK guidelines for the treatment of depression in CKD. 
However NICE guidelines for the management of depression in patients with chronic physical 
health problems (NICE, 2009) recommend use of antidepressants in this group of patients for 
those with moderate or severe depression, mild depression that complicates the care of the 
physical health problem, an initial presentation with subthreshold depressive symptoms (less 
than 5) present for over 2 years, and subthreshold depressive symptoms or mild depression 
persisting after other interventions. NICE make other recommendations for the management 
of patients initiated on antidepressants including the timing of review and the indications for 
dose escalation and switch to alternative therapy.  
To study the natural history of antidepressant medication in patients on HD and ascertain 
adherence to these guidelines we followed up patients in the ASSertID study, who were on 
antidepressants at baseline screening (and therefore excluded from the RCT phase of the 
ASSertID study), some 6-15 months later (Friedli et al., 2017). At follow-up, baseline screening 
tests were repeated, and a full clinical and psychiatric history was obtained, including a formal 
diagnostic interview.  
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MATERIALS AND METHODS 
Ethics 
Ethical approval was obtained (REC reference number 14/EE/0143). The study was 
sponsored by East and North Herts NHS Trust. All patients provided appropriate informed 
consent in keeping with the Helsinki agreement.  
Patients.  
We selected patients using screening data from the ASSertID study. In ASSertID, 709 
unselected HD patients were screened for high depression scores (BDI-II ≥ 16) to identify 
patients suitable for the RCT phase of ASSertID. Being on antidepressants was an exclusion 
criterion for the RCT phase of ASSertID – which compared the effect of sertraline and 
placebo on major depression. Hence, though patients on antidepressants were excluded 
from the ASSertID RCT, they were eligible for the follow-up study, which is the subject of 
this paper. These patients were approached by the research psychiatrist, asked if they were 
interested in taking part in the follow-up study, and provided with a participant information 
sheet. If the patient expressed an interest in participating, a follow-up appointment with the 
study psychiatrist was arranged, at which written consent was obtained. 
Data collection 
Baseline data 
o Demographics - date of birth, gender, ethnicity, marital status, and social 
class/education, social support. 
o Primary renal disease, date of starting renal replacement therapy, and 
transplantation history 
o Weight, estimated urine output (cupfuls per day) 
o Comorbidities including the presence of: heart disease, stroke, amputation of 
limbs, diabetes, cancer, liver disease, lung disease.  
o Past history and treatment of depression or anxiety. Any other involvement 
with psychology or psychiatry services 
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o Haemoglobin, urea and electrolytes, serum albumin, calcium and phosphate, 
and Kt/V.  
o Screen for depression symptoms with Beck Depression Inventory-II (BDI-II) 
(Beck et al., 2000). This is a standard screening tool for depression symptoms 
usually used to identify people high scores which are suggestive of major 
depressive disorder prior to consideration of referral for psychiatric 
evaluation. Because of the overlap of uraemic and depressive symptoms the 
cut-off score is set higher at ≥16 in HD patients than in the general population 
(Watnick et al., 2005, Chilcot et al., 2008b). Patients also completed the Patient 
Health Questionnaire-9 (PHQ-9)(Kroenke et al., 2001) for which the validated 
cut-off score is 10 (Watnick et al., 2005). 
 
Follow-up data 
o Full medical and psychiatric history 
o History of psychotropic medications and primary prescriber 
o Changes in psychological or psychiatric treatment since screening 
o Hospital admissions, change in comorbidities and medication since screening 
o Major clinical and social events since screening  
o Repeat screening with BDI-II and PHQ-9 
o Diagnostic interview including the Mini-International Neuropsychiatric 
Interview (MINI) (Sheehan et al., 1998) to identify the diagnosis of MDD  
o Antidepressant adherence and beliefs using Medication Adherence Rating 
Scale (MARS) (Thompson et al., 2000) and Beliefs about Medications 
Questionnaire (BMQ) (Horne and Weinman, 1999) 
 
Statistical analysis  
The cohort was characterised in terms of the screening data and the additional data collected 
on the patients' history, using descriptive statistics. Differences between baseline and follow-
up parameters were assessed by the paired t test or Wilcoxon signed rank test as appropriate. 
Other group differences were assessed by t-tests or Mann-Witney tests as appropriate. Group 
differences in proportions were assessed by the Chi-squared test. Differences between 
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multiple groups were assessed using ANOVA or the Kruskal-Wallis as appropriate. Logistic 
regression analysis was carried out to determine predictors of current depression. The setting 
in which the antidepressant therapy was commenced (primary care, nephrology, psychiatry), 
and the degree to which subsequent management was consonant with relevant NICE 
guidelines was analysed descriptively. Analyses were carried out using SPSS version 23 (IBM 






Seventy-six patients out of the 709 screened (11%) in the ASSertID study, were taking 
antidepressants at the time of screening. At the time of follow-up, six had been transplanted, 
one had been transferred to another renal unit, 12 had died, and two refused consent. We 
could not follow-up any of the patients at one centre for logistic reasons (Figure 1). The 
demographic and clinical characteristics of the remaining 41 patients are shown in Table 1. 
Ten different antidepressant agents were being taken (Table 2), the most common being 
Citalopram (39%). The primary prescribers of antidepressants were General practitioners 
(68%) followed by nephrologists (22%), and psychiatrists (10%).  
 
Follow-up data is shown in Table 3. There were no significant differences between baseline 
and follow-up with respect to patient dry weight, pre- and post-dialysis BP, haemoglobin, 
albumin, and calcium, phosphate and Kt/V (data not shown). Twenty patients had life events 
and 19 had clinical events during follow-up. Fourteen had both. There was a significant 
reduction in BDII-II score over the course of the study (26 (IQR 19) to 21 (IQR 17): p=0.015). 
PHQ-9 score fell but not significantly (12 (IQR 9) to 10.5 (IQR 10): p=0.091).  
 
At baseline, 30 patients had a BDI-II score ≥16, indicating high depressive symptoms. Of these, 
22 remained with high depressive symptoms at follow-up while eight improved (BDI-II <16 at 
follow-up). Those who improved had lower BDI-II scores (23 (IQR 10) vs 31.5 (IQR 14): p= 
0.006) at baseline, lower dialysis vintage (44.2 (IQR 37.6) vs 79.8 (IQR 50) months: p=0.035), 
and fewer were anuric (8% vs 41%: p=0.04). Age, gender, ethnicity, marital status, 
comorbidity, haematological and biochemical profile, and clinical events during follow-up, did 
not differ.  Of the 11 with BDI-II <16 at baseline, five had increased their BDI-II score to ≥16 at 
follow-up. These tended to be younger, 61 ± 12 vs 68 ± 21 years, of greater dialysis vintage 
(42.1 (176) vs 29.1 (IQR 21.1)) and with higher baseline BDI-II score (10 (IQR 6) vs 7.5 (IQR 7)), 
though none of these changes was statistically significant. No differences in comorbid load 
were apparent, though baseline serum albumin was lower in those who deteriorated (32.6 ± 
5.1 v 38.8 ± 1.6: p=0.019) and more patients in this group had experienced clinical events, 
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including below-knee amputation and stroke during follow-up (80% vs 17%: p=0.036). 
Patients who were married/partnered were also less likely to have high depressive symptoms 
in relation to BDI-II (17% vs 80%: p= 0.036).  
 
There had been no review of antidepressant medication during follow-up in 16 patients (39%). 
Fourteen (34%) had had a dose review. A change in antidepressant medication had occurred 
in 11 (27%). Most of these changes were instigated by GPs. A significant proportion of patients 
were taking agents cautioned against or with no available prescribing information in HD 
patients or taking doses that might be considered sub-therapeutic. 
 
Twenty-seven of the 41 patients (66%) either deteriorated or failed to improve during follow-
up (Table 4). There were no differences between these and others with respect to 
demographic, clinical, or biochemical parameters, except that they tended to have 
experienced more clinical events during follow-up (58% vs 29%: p = 0.079). They also had 
significantly higher BDI-II and PHQ-9 scores at baseline screening and significantly lower 
necessity scores on the BMQ questionnaire (Table 4). There were no differences with respect 
to BMQ concerns scores and no differences in MARS scores. In logistic regression analysis 
(Nagelkerke R square = 0.440), the independent predictors of deterioration or failure to 
improve were dialysis vintage (months) (odds ratio 1.046: p = 0.012) and clinical events (odds 
ratio 7.118: p = 0.026). Although two-thirds of patients deteriorated or failed to improve 
during follow-up, only 11 changes in antidepressant prescription (27%) were made during that 
time.  
 
Patients underwent formal psychiatric examination at follow-up. Based on the MINI, eight 
patients had current major depressive disorder (MDD), seven recurrent, 20 had past MDD, 
and six displayed no evidence of ever having had MDD (Table 5). Though there were 
differences between the groups with respect to age, gender distribution, comorbidity profile, 
baseline depression scores, clinical and life events during follow-up the only significant 
differences related to follow-up BDI-II and PHQ-9 scores, which were higher in those with 
current or recurrent depression. Presumably the lack of significance in other parameters 
11 
 
relates to the small numbers in each of the groups. All 15 patients with current or recurrent 
MDD at follow-up were among the 27 whose BDI-II scores deteriorated or did not improve 
during follow-up (Figure 2). Most of the other 27 patients were found to have evidence of 
past MDD on psychiatric examination though interestingly 2 patients appeared never to have 
experienced MDD. A change of prescription during follow-up occurred in only four patients 
of the 15 patients (27%) with current or recurrent MDD. The six patients in the  group in which 
there was no evidence of present or past MDD were significantly older than all others [median 





Two-thirds of HD patients who were taking antidepressants at baseline had persistently high 
or deteriorating depressive symptom scores after a mean follow-up of 14 months. A high 
proportion of these (56%) had clinical depression as diagnosed by the MINI. In addition 15% 
of the cohort had no evidence of ever having had MDD over their lifetime according to the 
MINI, in spite of their being on antidepressants.  
 
In most cases antidepressant treatment was initiated in primary care rather than by 
nephrologists. There may be a number of reasons. Nephrologists may be more likely to think 
that depression is 'part of the illness and/or its treatment'. They may also be much more 
aware of the complexity of this cohort in terms of comorbidity and polypharmacy with its 
hugely increased potential for adverse drug effects and interactions, making them reluctant 
to add to the tablet burden. Notwithstanding this, it is also not clear what assessments had 
been made in primary care prior to initiation. NICE recommends that if “a patient with a 
chronic physical health problem answers 'yes' to either of the depression identification 
questions but the practitioner is not competent to perform a mental health assessment, they 
should refer the patient to an appropriate professional”. However only 10% of patients had 
therapy initiated by a psychiatrist. MINI examination at follow-up found no evidence of prior 
depression in 15% of patients, suggesting potential overprescribing. This is particularly 
relevant given the difficulties of diagnosing depression in the setting of advanced CKD, 
stemming from the overlap of symptoms directly attributable to kidney failure and those of 
depression (Chilcot et al., 2008a). The treatment initiation issue also highlights the need for 
effective communication between the GP and the nephrologist. 
 
In terms of the choice of agent NICE recommends “First prescribe an SSRI in generic form 
unless there are interactions with other drugs; consider using citalopram or sertraline 
because they have less propensity for interactions”. We found that 10 different agents were 
being used in these 41 patients. The commonest (39% of prescriptions) was citalopram which 
is in line with these recommendations. However recent evidence suggests that SSRIs 
associated with significant QT interval prolongation, such as citalopram, are associated with 
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an increased risk of sudden cardiac death in patients on HD compared to those with less 
propensity for QT prolongation such as sertraline (Assimon et al., 2019). Similar 
considerations apply to escitalopram (5% of prescriptions) (Assimon et al., 2019). A few 
patients (5%) were taking tricyclic antidepressants, despite these being contraindicated for 
patients with heart disease. This may be especially risky in HD patients as heart disease is very 
common in this population, and is the prime cause of death. 
 
 It was also apparent that a high proportion of patients had no review or amendment of their 
antidepressant prescription during follow-up. NICE recommends that, if there is an 
inadequate response after 4 weeks treatment with a therapeutic dose of an antidepressant 
that the level of support should be increased, and that dose increase or switch to another 
antidepressant should be considered. We do not know the full trajectory of antidepressant 
medication in these patients, though it does appear that many had inadequate follow-up, 
may have been receiving sub-therapeutic doses, or both. This raises questions about the safe 
and effective use of antidepressants in this setting. However, given the lack of evidence of the 
efficacy of these agents in this setting, and their propensity to increase adverse events, we 
cannot predict that full adherence to the guidelines would necessarily translate into patient 
benefit. 
 
A high proportion of patients had high depressive symptoms at follow up and many of these 
were found to have major depressive disorder. The main factors associated with high 
depression scores (BDI-II ≥16) at follow-up were high baseline depression scores, higher 
dialysis vintage and adverse clinical events during the follow-up period. This suggests that 
changes in situational/exogenous drivers of depression over the interval of study may have 
influenced the depression measurements, the responses to medication, and the indications to 
escalate therapy. Patients with high scores also had lower BMQ necessity scores, suggesting 
that people who think the medication is necessary may respond better or may adhere better to 
the treatment recommendations. This though was not significant in multivariate analysis.  
 
We have previously discussed the limited evidence base for antidepressant medication in 
patients on haemodialysis. Though there is a little more evidence for the efficacy of CBT, the 
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benefits shown were short term (Duarte et al., 2009, Cukor et al., 2014) and a recent study 
has suggested a marginal benefit of sertraline over CBT (Mehrotra et al., 2019). We need 
further research on both pharmacological and non-pharmacological approaches to the 
treatment of depression in this setting. This should include studies aimed at optimising the 
use of currently available treatment options as well as the investigation of more novel 
approaches including multimodal antidepressants, augmentation strategies using atypical 
antipsychotics (Ceskova and Silhan, 2018) and use of neuromodulation techniques including 
transcranial magnetic stimulation (Bewernick and Schlaepfer, 2015). To our knowledge there 
is currently no literature on use of these newer approaches in advanced CKD. 
 
There are a number of limitations to our study which need to be borne in mind in its 
interpretation. In the general population the average depressive episode lasts about nine to 12 
months without treatment, although around 20% run a chronic course of two years or longer. 
Once established, chronic episodes last an average of five to eight years (Wittchen and Jacobi, 
2005). This may be a contributory factor to our finding that many patients' antidepressant status 
remaining essentially unchanged during follow-up. Another factor may be difficulty stopping 
these agents due to withdrawal effects which may be intense and prolonged (Davies and Read, 
2019, Horowitz and Taylor, 2019). These may mimic aspects of depression and indeed some 
uraemic symptoms. It may be that withdrawal is particularly difficult in this setting. In addition 
a significant proportion of patients on HD are elderly, frail, functionally impaired and their 
prognosis is poor. It is difficult to estimate just how responsive such patients may be to 
treatment with antidepressants. 
 
In summary, a significant proportion of the HD population takes antidepressant medication. 
Our findings suggest multiple problems with their use this setting. Most initiation and 
management of antidepressant medication was carried out in General Practice mandating 
effective communication with nephrology services. Multiple types of antidepressants were 
being used, a number of which may be potentially problematic in this setting. There was 
evidence of over-prescription – in 15% of patients there was no firm evidence of current or 
past depression. There was inadequate follow-up reflecting sub-optimal adherence to NICE 
guidelines. In addition, recent randomised studies have failed to confirm efficacy of these 
agents in the CKD population whilst demonstrating significant issues with adverse effects. 
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Furthermore there is some evidence of increased mortality risk with some of these agents. This 
suggests the need for a major reappraisal of the use of these agents in this setting. 
 
Implications for clinical practice 
Management of depression in haemodialysis patients is difficult. Diagnosis is problematic due 
to the overlap between symptoms of kidney disease and depression. There are doubts too about 
the efficacy of antidepressant agents in this setting. In addition there is an increased potential 
for adverse effects and drug interactions when these agents are used in advanced kidney 
disease. This study also suggests that suboptimal use of these agents in this setting is 
widespread. Further research would inform renal specific recommendations. In the meantime, 
there is ample scope to optimise the use of antidepressants in every day clinical practice though 
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Figure 1. Flow diagram of fate of 709 screened patients over ensuing 6-15 months. Forty-one of the 





Figure 2. Flow diagram of results of depression symptom screening at baseline and follow-up, 
together with results of MINI psychiatric examination at follow-up. BDI-II Beck Depression Inventory 





























Table 1. Baseline characteristics of 41 haemodialysis patients on antidepressants. BDI-II Beck 
Depression Inventory version 2. PHQ-9 Patient Health Questionnaire-9. Kt/V normalised urea 
clearance per dialysis session. IQR – interquartile range. 
Age (years) 62 ± 16 
Gender (% male) 63 
Ethnicity (% white) 73 
Married/partner (%) 49 
Single (%) 27 
Divorced (%) 12 
Widowed (%) 12 
Diabetes (%) 42 
Vintage (IQR) months 42 (56.4) 
Heart disease (%) 37 
Cancer (%) 22 
Amputation (%) 5 
Weight (kg) 81 ± 23 
Pre-dialysis systolic BP (mmHg) 140 ± 27 
Pre-dialysis diastolic BP (mmHg) 75 ± 17 
Haemoglobin (g/l) 110 ± 13 
Albumin (g/l) 39 ± 4.2 
Calcium (mmol/l) 2.26 ± 0.26 
Phosphate (mmol/l) 1.50 ± 0.48 
Kt/V  1.33 ± 0.31 
Previous psychological therapy (%) 32 
BDI-II 26 (IQR 19) 





Antidepressant Number of patients Dose range 
Citalopram 16 (39%) 10mg (2), 20mg (10), 30mg (3), 40mg (1) 
Fluoxetine  9 (22%) 20mg (8), 40mg (1) 
Sertraline 6 (15%) 50mg 
Mirtazapine  2 (5%) 30mg 
Venlafaxine  2 (5%) 225mg (1), 75mg (1) 
Escitalopram  2 (5%) 10mg (1), 15mg (2) 
Paroxetine  1 (2%) 10mg 
Dothiepin  1 (2%) 100mg 
Nortriptyline  1 (2%) 40mg 
Duloxetine  1 (2%) 60mg 
 






Mean follow-up (month) 14 ± 5 
Primary prescriber  
GP 28 (68%) 
Nephrologist 9 (22%) 
Psychiatrist 4 (10%) 
Medication review  
Antidepressant agents used 10 
Dose change 14 (34%) 
Medication change 11 (27%) 
None 16 (39%) 
Events  
Life/social event (%) 20 (49%) 
Clinical event (%) 19 (46%) 
Depression screening  
BDI-II 21 (IQR 17) 
PHQ-9 10.5 (IQR 10) 
MINI diagnosis  
Current MDE 8 (20%) 
Recurrent MDE 7 (17%) 
Past MDE 20 (48%) 
No MDE 6 (15%) 
 
Table 3. Follow up data on 41 HD patients on antidepressants at baseline screening. GP general 
practitioner. MDE major depressive episode. BDI-II Beck Depression Inventory version 2. PHQ-9 












Numbers 27 14  
Age (years) 60 ± 15 67 ± 18 NS 
% Male 56 79 NS 
% Married/partner 41 64 NS 
% Clinical events 58 29 0.079 
% Life events 54 43 NS 
% Heart disease 37 36 NS 
% Diabetes  44 36 NS 
% Cancer 26 14 NS 
Dialysis vintage (months) 71.1 (50) 42.2 (37.6) 0.005 
BDI-II (baseline) 28 (17) 17 (18) 0.002 
PHQ-9 (baseline) 14.5 (7) 7.5 (8) 0.005 
BMQ necessity score 12.2 ± 3 14.5 ± 2.8 0.022 
BMQ concerns score 12.7 ± 2.8 13.3 ± 2.5 NS 
MARS score 7.9 ± 1.5 8.6 ± 1.1 NS 
 
 
Table 4. Comparison of patients at follow-up whose depression scores were ≥16 at baseline 
screening and deteriorated or failed to improve during follow-up (depressed) and those who 
remained with BDI-II score < 16 or improved to that level from higher baseline scores (non-
depressed). BDI-II Beck Depression Inventory version 2. PHQ-9 Patient Health Questionnaire-9. BMQ 




 Major Depressive Disorder (MINI Diagnosis)  
 Current Recurrent Past Never  
Number 8 7 20 6  
Baseline      
Age (years) 63 ± 11 58 ± 20 60 ± 17 73 ± 12 NS 
% Male 75 43 65 67 NS 
% Married/partner 63 29 45 67 NS 
% Heart disease 63 29 30 33 NS 
% Diabetes  63 57 25 50 NS 
% Cancer 38 14 15 33 NS 
Dialysis vintage (months) 5.2 (6.2) 5.7 (5.7) 4.3 (4.9) 3.1 (2.2) NS 
BDI-II baseline 32 (17) 18 (16) 26.5 (14) 14.5 (27) NS 
PHQ-9 baseline 12 (6) 9 (10) 12 (9) 7.5 (16) NS 
Follow-up      
% Clinical events 63 71 40 20 NS 
% Life events 50 71 40 60 NS 
BDI-II – follow-up 28 (13) 27 (12) 16.5 (15) 11 (23) 0.006 
PHQ-9 – follow-up 13 (7) 14 (5) 7.5 (6) 6.5 (13) 0.023 
BMQ (necessity) 11.4 ± 2.9 13.1 ± 3.1 13.2 ± 2.9 14.2 ± 3.8 NS 
BMQ (concerns) 12.1 ± 2.5 12.7 ± 3.6 13.5 ± 2.6 12.3 ± 3.3 NS 
MARS (adherence) 8.1 ± 1.5 7.4 ± 1.7 8.5 ± 1.4 8.2 ± 1.0 NS 
 
Table 5. Comparison of baseline and follow-up characteristics based on MINI diagnosis at follow-up. 
BDI-II Beck Depression Inventory version 2. PHQ-9 Patient Health Questionnaire-9. BMQ Beliefs 
about Medication Questionnaire. MARS Medication Adherence Rating Scale. 
 
